Dr. Salim Dhanji reports

ME THERAPEUTICS ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT

ME Therapeutics Holdings Inc. has closed its previously announced non-brokered private placement financing and has issued 1,555,000 units at a price of $1 per unit, raising gross proceeds of $1,555,000.

Each unit comprises one common share of the company and one share purchase warrant. Each warrant entitles the holder thereof to purchase one additional share at a price of $1.50 per share for a period of two years from the closing of the offering, subject to an acceleration provision whereby the expiry date of the warrants may be accelerated if the daily trading price of the shares equals or exceeds $2 on the Canadian Securities Exchange (or such other exchange on which the shares may then be traded) for a period of 10 consecutive trading days in which event the company may, in its discretion, accelerate the expiry date of the warrants by giving notice via news release and, in such case, the warrants will expire on the 30th day after the date on which the news release is disseminated.

All securities issued in connection with the offering are subject to a statutory hold period expiring four months and one day after the date of the closing. No finder's fees were paid in connection with the offering.

The aggregate gross proceeds from the offering are expected to be used for financing continuing research and development of the company's technology, regulatory review and approvals, potential in-licensing or partnerships, operating expenses, investor relations, and other working capital requirements.

About ME Therapeutics Holdings Inc.

Myeloid Enhancement (ME) Therapeutics is an early-stage Vancouver-based biotechnology company involved in the discovery and development of novel immuno-oncology therapeutics targeting immune suppression in cancer. Its main focus is on overcoming the suppressive effects of an important class of immune cells called myeloid cells in order to enhance anti-cancer immunity.

We seek Safe Harbor.